Skip to search formSkip to main contentSkip to account menu

ipilimumab

Known as: MOAB-CTLA-4, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, monoclonal antibody CTLA-4 
A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4… 
National Institutes of Health

Related topics

Related topics

16 relations
10 ML ipilimumab 5 MG/ML Injection10 ML ipilimumab 5 MG/ML Injection [Yervoy]CP-675,206CTLA4 protein, human

Narrower (3)

BMS-734016MDX-010Yervoy

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Baseline neutrophil to lymphocyte ratio combined with serum LDH level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population
This article has been accepted for publication and undergone full peer review but has not been through the copyediting… 
2017
2017
Management of dermatological adverse events during nivolumab treatment
Programmed death 1 receptor (PD-1) inhibitors, such as nivolumab, are effective in the treatment of advanced and metastatic… 
2016
2016
Mutation burden and tumor neoantigens in RCC patients (pts) treated with nivolumab.
514 Background: Durable benefit with CTLA4 or PD1 blockade associates with high somatic mutation burden in melanoma and lung… 
2015
2015
Survival, biomarker, and toxicity analysis of nivolumab (NIVO) in patients that progressed on ipilimumab (IPI).
9055 Background: PD-1 antibodynivolumab was administered with/without a multi-peptide vaccine to 126 patients (pts) with… 
2015
2015
Granuloma Annulare in the Setting of Ipilimumab Therapy
We present a patient who developed granuloma annulare during ipilimumab therapy. Many adverse events of ipilimumab therapy are… 
2015
2015
Pembrolizumab superior to ipilimumab in melanoma.
In the first randomized trial to compare FDA-approved immune checkpoint inhibitors as first-line therapy for patients with… 
Review
2013
Review
2013
Key issues in the management of gastrointestinal immune-related adverse events associated with ipilimumab administration
Ipilimumab is an anticytotoxic T lymphocyte antigen-4 (CTLA-4) monoclonal antibody that attenuates negative signaling from CTLA-4… 
2012
2012
New class of kinase inhibitors poised to join the anticancer arsenal
Long-standing efforts to develop drugs that target MEKs could soon come to fruition, moving the frontier to how best to combine… 
2012
2012
Ipilimumab: Developmental History, Clinical Considerations, and Future Perspectives
Ipilimumab (commercial name YervoyTM, Bristol-Myers Squibb, Princeton, NJ) was approved on March 25, 2011 by the US Food and Drug… 
2011
2011
Dual fronts poised to transform melanoma therapy
With recent successes of immunotherapies and targeted drugs, melanoma has become one of the most dynamic areas of anticancer drug…